Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future (original) (raw)
References
Wall ME, Wani MC, Cook CE, Palmer KH, McPhail HT, Sim GA: Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888–3890, 1966 Google Scholar
Roca J: The mechanisms of DNA topoisomerases. Trends Biochem Sci20: 156–160, 1995 Google Scholar
Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug stabilised topoisomerase 1-DNA complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082, 1989 Google Scholar
Chen AY, Liu LF: Mechanisms of resistance of topoisomerase inhibitors. Cancer Treat Res 73: 263–281, 1994 Google Scholar
Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJC: An overview of the clinical pharmacology of topotecan. Semin Oncol 24(Suppl 5): 12–18, 1997 Google Scholar
Eng WK, Faucette L, Johnson RK, Sternglanz R: Evidence that DNA topoisomerase 1 is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755–760, 1988 Google Scholar
Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase 1 as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722–1726, 1988 Google Scholar
Gottlieb JA, Guarino AM, Call JB, Olivero VT, Block JB: Preliminary pharmacologic and clinical evaluation of the camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461–470, 1970 Google Scholar
Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS: Phase 1 clinical trial of weekly and daily treatment with camptothecin (NCS-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515–521, 1972 Google Scholar
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase 2 study with camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95–101, 1972 Google Scholar
Creaven PJ, Alien LM, Muggia FM: Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: Relation to dose and toxicity. Cancer Chemother Rep 56: 573–578, 1972 Google Scholar
Hsiang YH, Hertzberg R, Hecht S, and Liu LF: Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerase 1. J Biol Chem 260: 14873–14878, 1985 Google Scholar
Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase 1 targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046–1048, 1989 Google Scholar
van der Zee AG, Hollema H, de Jong S, Boonstra H, Grouw A, Willemse PHB, Zijlstra JG, de Vries EGE: P-glycoprotein expression and DNA topoisomerase 1 and 2 activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclofosfamide chemotherapy. Cancer Res 51: 5915–5920, 1991 Google Scholar
ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15(6): 2183–2193, 1997 Google Scholar
van Cutsem E, Blijham GH: Irinotecan versus infusional 5-fluorouracil: a phase 3 study in metastatic colorectal cancer following failure on first-line fluorouracil. V302 study group. Semin Oncol 26(1 Suppl 5): 13–20, 1999 Google Scholar
Burris HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD: Activity of topotecan, a new topoisomerase 1 inhibitor against human tumor colony forming units in vitro. J Natl Cancer Inst 23: 1816–1820, 1992 Google Scholar
Houghton PJ, Chesire PJ, Myers L, Stewart CF, Synold TW, Houghton JA: Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 31: 229–239, 1992 Google Scholar
Houghton PJ, Chesine PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA: Efficacy of topoisomerase 1 inhibitors topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393–430, 1995 Google Scholar
Giovanella BC, Hint HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052–3055, 1991 Google Scholar
Giovanella BC, Stehlin JS, Hint HR, Vardeman D, Mendoza JT, Potmesil M: Studies of time/dose intensity in treatment of human cancer xenografts with camptothecin analogues (abstract). Proc AACR 35: 2713, 1994 Google Scholar
Pantazis P, Hin HR, Mendoza JT, Kozielski AJ, Williams LJ, Stehlin JS, Giovanella BC: Complete inhibition of growth followed by death of human malignant xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980–3987, 1992 Google Scholar
Pantazis P, Kozielski A, Rodriguez R, Petry E, Wani M, Wall M, Giovanella B: Therapeutic efficacy of camptothecin derivates against human melanoma xenografts. Melanoma Res 4: 5–10, 1994 Google Scholar
Phillips PC, Janss A, Kaufmann SH, Levow C, Yao Y, Colvin OM: Topoisomerase 1 inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumor cell lines (abstract). Proc AACR 35: 2161, 1994 Google Scholar
Potmesil M, Liebes L, Drygas J, Sekiya S, Morse L, Kozielski AJ, Wall ME, Wani MC, Stehlin JS, Giovanella BC: Pharmacodynamics/pharmacokinetics of intragastric camptothecin analogs in a human cancer xenograft model (abstract).Proc AACR 36: 2652, 1995 Google Scholar
Daoud SS, Fetouh MI, Giovanella BC: Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anti-Cancer Drugs 6: 83–93, 1995 Google Scholar
Stevenson JP, Scher RM, Kosierowski R, Fox SC, Simmonds M, Yao K-S, Green F, Broom C, Fields SZ, Krebs JB, O'Dwyer PJ: Phase 2 trial of topotecan as a 21-day continous infusion in patients wit.h advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 34(9): 1358–1362, 1998 Google Scholar
Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH: Phase 1 trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553–559, 1994 Google Scholar
Hochster H, Potmesil M, Liebes L, Sorich J, Taubes B, Dewey D, Oratz R, Chachoua A, Speyer J: A phase 1 study of 9-amino-camptothecin (9-AC) by prolonged infusion over 21 days (abstract). NCI-EORTC 9th symposium on new drugs in cancer therapy: 461,Amsterdam, the Netherlands, March 1996 Google Scholar
Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A: Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase 1 and pharmacodynamic study. Clin Cancer Res 3: 1245–1252, 1997 Google Scholar
Hochster H, Speyer J, Wadler S, Runowicz C, Wallach R, Oratz R, Chachoua A, Sorich J, Taubes B, Ludwig E, Broom C, Blum R: Phase 2 study of topotecan 21-day infusion in platinum-treated ovarian cancer: a highly active regimen (abstract). Proc ASCO 15: 775, 1996 Google Scholar
Herben VMM, ten Bokkel Huinink WW, Schot ME, Hudson I, Beijnen JH: Continuous infusion of low dose topotecan: pharmacokinetics and pharmacodynamics during a phase 2 study in patients with small cell lung cancer. Anti-Cancer Drugs 9: 411–418, 1998 Google Scholar
Herben VMM, Schellens JHM, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW: Phase 1 and pharmacokinetic study of irinotecan administered as a low dose continuous infusion over fourteen days in patients with malignant solid tumours. Thesis Herben 1998
Kyritsis A, Newlands ES, Brock CS, Gleason M, Jaeckle K, Levin V, Bower M, Evans DG, DeWitte M, Yung W: Phase 2 trial of topotecan as a continous intravenous infusion in patients with high grade gliomas (abstract). Proc ASCO 16: 1404, 1997 Google Scholar
Kindler HL, Kris MG, Smith IE, Miller VA, Grant SC, Krebs JB, Ross GA, Slevin ML: Phase 2 study of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small cell lung cancer. Am J Clin Oncol 21: 438–441, 1998 Google Scholar
Creemers GJ, Gerrits CJH, Schellens JHM, Planting ASTh, van der Burg MEL, van Beurden VM, de Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J: Phase 2 and pharmacologic study of topotecan administered as a 21-days continous infusion to patients with colorectal cancer. J Clin Oncol 14: 2540–2545, 1996 Google Scholar
de Jonge MJA, Punt CJA, Gelderblom AH, Loos WJ, van Beurden V, Planting ASTh, van der Burg MEL, van Maanen LWGM, Dallaire BK, Verweij J, Wagener DJT, Sparreboom A: Phase 1 and pharmacologic study of oral (PEG-1000)9-Aminocamptothecin in adult patients with solid tumors. J Clin Oncol 17: 2219–2226, 1999 Google Scholar
Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallaher G, Caranfa MJ, McGabe FL, Faucette LF, Johnson RK: Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase 1 and antitumor activity. J Med Chem 34: 913–107, 1991 Google Scholar
Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verweij J: Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase 1 inhibitor. Br J Cancer 73: 1268–1271, 1996 Google Scholar
Kuhn J, Rizzo J, Eckardt J, Fields S, Cobb P, Rodriguez G, Rinaldi D, Drengler R, Smith L, Peacock N, Thurman A, DeLaCruz P, Hodges S, Von Hoff D, Burris H: Phase 1 biovailability study of oral topotecan (abstract). Proc ASCO 14: 1538, 1995 Google Scholar
Herben VMM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E, Beusenberg FD, Beijnen JH, Schellens JHM: A new oral dosage form of topotecan: Bioavailability and effect of food coadministration. Br J Cancer 80: 1380–1386, 1999 Google Scholar
Creemers GJ, Gerrits CJH, Eckhardt JR, Schellens JHM, Burris HA, Planting AST, Rodriguez GJ, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD: Phase 1 and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15: 1087–1093, 1997 Google Scholar
Hochster A, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum R, Zleniuch-Jacquotte A: Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase 1 and pharmacodynamic study. Clin Cancer Res 3. 1245–1252, 1997 Google Scholar
Gerrits CJH, Burris H, Schellens JHM, Eckardt JR, Planting AST, van der Burg MEL, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J: Oral topotecan given once or twice daily ten days: a phase 1 pharmacology study in adult patients with solid tumors. Clinical Cancer Res 4: 1153–1158, 1998 Google Scholar
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RS: Phase 1 and pharmacologic study of topotecan: a novel topoisomerase 1 inhibitor. J Clin Oncol 10: 647–656, 1992 Google Scholar
van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, de Boer-Dennert M, Maes RAA, Beijnen JH: Pharmacokinetics and pharmacodynamics of topotecan administered in a daily times five regimen every three weeks. Cancer Chemother Pharmacol 35: 237–245, 1995 Google Scholar
Verweij J, Lund B, Beijnen JH, Planting A, de Boer-Dennert M, Koier I, Rosing H, Hansen H: Phase 1 and pharmacokinetic study of topotecan, a new topoisomerase 1 inhibitor. Ann Oncol 4: 673–678, 1993 Google Scholar
Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D: Phase 1 clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colonystimulating factor. J Natl Cancer Inst 85: 1499–1507, 1993 Google Scholar
Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D: Phase 2 study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14: 2345–2352, 1996 Google Scholar
Ardizanni A, Hansen HH, Dombernowsky P, Gamucci T, Kaplan S, Postmus PE, Giaccone G, Schaefer B, Wanders J, Verweij J: Topotecan, a new active drug in the second line treatment of small-cell lung cancer: a phase 2 study in patients with refractory and sensitive disease. The EORTC of Cancer Early Clinical Studies and NDDO, and the Lung Cancer Cooperative group. J Clin Oncol 15: 2090–2096, 1997 Google Scholar
Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ: Phase 2 study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14: 1552–1557, 1996 Google Scholar
Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J, McGuire W: A phase 2 trial of topotecan as salvage therapy in epithelian ovarian cancer (abstract). Proc ASCO 14: 769, 1995 Google Scholar
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favelli G, Kleinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW: Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: results of a large European phase 2 study. J Clin Oncol 14: 3056–3061, 1996 Google Scholar
Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ: Topotecan for the treatment of advanced epithelial ovarian cancer: an openlabel phase 2 study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345–3352, 1998 Google Scholar
von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleibauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R: Topotecan versus cyclofosfamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17: 658–667, 1999 Google Scholar
Gerrits CJH, Burris H, Schellens JHM, Planting AST, van der Burg MEL, Rodriguez GI, van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J, Von Hoff DD: Five days of oral topotecan (Hycamtin), a phase 1 and pharmacological study in adult patients with solid tumours. Eur J Cancer 34(7): 1030–1035, 1998 Google Scholar
Gerrits CJH, Schellens JHM, Burris H, Eckardt JR, Planting ASTh, van der Burg MEL, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J: A comparison of clinical pharmacodynamics of different schedules of oral topotecan (Hycamtin): Clin Cancer Res 5: 69–75, 1999 Google Scholar
von Pawel J, Gatzemeier U, Harstrick A, Ranson M, Richardson G, Steppert K, Camlett I, Lane S, Ross G: A multicentre randomised Phase 2 study of oral topotecan for second line therapy in sensitive patients with small cell lung cancer (abstract). Proc ASCO 18: 1816, 1999 Google Scholar
Gore M, Rustin G, Calvert H, Bezwoda W, Carmichael J, Oza A, Kaye S, Ten Bokkel Huinink W, Malfetano J, Falkson G, Clarke-Pearson D, Ross GA, Dane GC, Fields SZ: A multicentre, randomised, phase 3 trial of topotecan administered intravenously or orally for advanced epithelial ovarian carcinoma. Proc ASCO 17: 1346, 1998 Google Scholar
Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky E: Cytotoxic effects of topotecan combined with various anticancer agents in human cell lines. J Natl Cancer Inst 88: 734–741, 1996 Google Scholar
Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantification of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517–1524, 1994 Google Scholar
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F: _In vitro_and _in vivo_interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41: 385–390, 1998 Google Scholar
Kowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen T-L, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC: Sequences of topotecan and cisplatin: Phase 1, pharmacologic, and _in vitro_studies to examine sequence dependence. J Clin Oncol 14: 3074–3084, 1996 Google Scholar
Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F: Cellular pharmacology of the combination of the DNA topoisomerase 1 inhibitor SN-38 and the diaminocyclohexane platinum derivate oxaliplatin. Clin Cancer Res 5: 1189–1196, 1999 Google Scholar
Goldwasser F, Valenti M, Torres R, Kohn KW, Pommier Y: Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 2: 687–693, 1996 Google Scholar
Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JHM: Syneugistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solidtumor cell lines in vitro. Cancer Chemother Pharmacol 41: 307–316, 1998 Google Scholar
Raymond E, Burris HA, Rowinsky E, Eckardt JR, Rodriguez G, Smith L, Weiss G, Von Hoff DD: Phase 1 study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann Oncol 8: 1003–1008, 1997 Google Scholar
Miller AA, Hargis BJ, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL: Phase 1 study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol 12: 2743–2750, 1994 Google Scholar
Saltz L, Kanonitz J, Schwartz G, Kelsen D, Eng M, Baiano D, Spriggs D: Phase 1 trial of cisplatin (CDIDP) plus Topotecan (T) on a daily _ 5 schedule in patients with advanced solid tumors (abstract). Proc ASCO 14: 475, 1995 Google Scholar
Lilenbaum RC, Miller AA, Batist G, Hollis DR, Rosner GL, Schilsky RL, Ratain MJ: Phase 1 study of continuous iv infusion of topotecan in combination with cisplatin in patients with advanced cancer (CALCB)abstract. Proc ASCO 15: 485, 1996 Google Scholar
de Jonge MJA, Sparreboom A, Planting ASTh, de Boer-Dennert MM, Mantel MA, van der Burg MEL, Ross G, Stoter G, Verweij J: Sequence-dependent side effects of oral topotecan with intravenous cisplatin in a phase 1 and pharmacological study in patients with advanced solid tumors (abstract). Proc ASCO 17: 784, 1998 Google Scholar
Sparreboom A, De Jonge MJA, Loos WJ, Brouwer E, Doyle E, Hearn S, Verweij J: Sequence-independent clinical pharmacokinetics of intravenous cisplatin and oral topotecan (abstract). Proc AACR 40: 3879, 1999 Google Scholar
van der Burg MEL, Logmans A, de Wit R, van Lent M, Kruit WHJ, Stoter G, Verweij J: Weekly high dose cisplatin and daily oral vepesid: a highly active regimen for ovarian cancer patients failing on or relapsing after conventional platinum containing combination chemotherapy (abstract). Proc ASCO 15: 722, 1996 Google Scholar
van der Burg MEL, de Wit R, Stoter G, Verweij J: Phase 1 study of weekly cisplatin and weekly or 4-weekly taxol: a highly active regimen in advanced epithelian cancer (abstract). Proc ASCO 17: 1370, 1998 Google Scholar
Morton CL, Wadkins RM, Danks MK, Potter PM: The anticancer prodrug CPT-II is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59: 1458–1463, 1999 Google Scholar
Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, Pawlik CA, Houghton PJ, Potter PM: Comparison of activation of CPT-II by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 5: 917–924, 1999 Google Scholar
Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivate CPT-11, in the antitumor effect of CTP-II. Cancer Res 51: 4187–4191, 1991 Google Scholar
Rivory LP, Bowles MR, Robert J, Pond SM: Conversion of Irinotecan (CPT-II) to its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103–1111, 1996 Google Scholar
Tsuji T, Kaneda N, Kado N, Yokokura T, Yoshimoto T, Tsuru D: CPT-II converting enzyme from rat serum: purification and some properties. J Pharmacobio-dyn 14: 341–349, 1991 Google Scholar
Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF: Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res 4: 455–462, 1998 Google Scholar
Atsumi R, Okazaki O, Hakusui H: Metabolism of irinotecan to SN-38 in a tumor-isolated tumor model. Biol Pharm Bull 18: 1024–1026, 1995 Google Scholar
Danks MK, Morton CL, Pawlik CA, Potter PM: Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-II. Cancer Res 58: 20–22, 1998 Google Scholar
Rivory LP, Robert J: Identification and kinetics of a Sglucuronide metabolite of SN-38 in human plasma after administration of the camptothecine derivate irinotecan. Cancer Chemother Pharmacol 36: 176–179, 1995 Google Scholar
Rivery LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A, Pond SM, Robert J: Identification and properties of a major plasma metabolite of irinotecan (CPT-I1) isolate from the plasma of patients. Cancer Res 56: 3689–3694, 1996 Google Scholar
Dodds HM, Haaz MC, Riou JF, Robert J, Rivery LP: Identi-fication of a new metabolite of CPT-II (irinotecan). Pharmacological properties and activation to SN-38. J Pharmacol Ex Ther 281: 578–583, 1998 Google Scholar
De Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A: Determination of irinotecan (CPT-II) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr 698: 277–285, 1997 Google Scholar
Sparreboom A, De Bruijn P, De Jonge MJA, Loos WJ, Stoter G, Verweij J, Nooter K: Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr 712: 225–235, 1998 Google Scholar
Sparreboom A, De Jonge MJA, De Bruijn P, Brouwer E, Nooter K, Loos WJ, Van Alphen RJ, Mathijssen RHJ, Stoter G, Verweij J: Irinotecan (CPT-II) metabolism and disposition in cancer patients. Clin Cancer Res 4: 2747–2757, 1998 Google Scholar
Le Chevalier T, Ibrahim N, Chomy P, Riviere A, Monnier A, Magherini E, Pujol JL: A phase 2 study of irinotecan in patients with small cell lung cancer progressive after initial response to first line chemotherapy (abstract). Proc ASCO 16: 1617, 1997 Google Scholar
Baker L, Khan R, Lynch T, Savaraj N, Sandler A, Feun L, Schasser R, Hanover C, Petit R: Phase 2 study of irinotecan in advanced non-small cell lung cancer (abstract). Proc ASCO 16: 1658, 1997 Google Scholar
Tamaya T, Noda K, Sagawa T, Sekiba K, Yakushiji M, Taguchi T: Clinical study of CPT-II, a camptothecin derivate, on gynaecological malignancy (abstract). Proc ASCO 9: 189, 1990 Google Scholar
Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S: CPT-II in combination with cisplatin for advanced nonsmall-cell lung cancer. J Clin Oncol 10: 1775–1780, 1992 Google Scholar
Masuda N, Fukuaka M, Kudoh S, Matsui K, Kusonoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T, Yoshikawa A, Kubo A, Matsuura E, Nitta T, Takifuji N, Terakawa K, Negoro S: Phase 1 and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Eur J Cancer 68: 777–782, 1993 Google Scholar
Sugiyama T, Takeuchi S, Noda K, Yakushiji M & CPT-II study Group on Gynecologic Malignancy: Phase 1 study of irinotecan (CPT-II) in combination with cisplatin (CDDP) on cervical carcinoma (abstract). Proc ASCO 13: 268, 1994 Google Scholar
Kobayashi K, Shinbara A, Kamimura M, Takeda Y, Kudoh K, Kabe J, Hibino S, Hino M, Shibuya M, Kudoh S: Irinotecan (CTP-II) in combination with weekly administration of cisplatin (CDDP) in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 32: 53–58, 1995 Google Scholar
Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama HT, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S: Phase 1– 2 study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. 7 Clin Oncol 15: 921–927, 1997 Google Scholar
Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Segawa Y, Chikkamori K, Yonei T, Hiraki S, Harada M: Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase 1 study. Br J Cancer 79: 984–990, 1999 Google Scholar
Mori K, Ohnishi T, Yokoyama K, Tominaga K: A phase 1 study of irinotecan and infusional cisplatin for advanced nonsmall-cell lung cancer. Cancer Chemother Pharmacol 39: 327–332, 1997 Google Scholar
Saltz LB, Spriggs D, Schaaf L, Schwartz G, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D: Phase 1 clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 16: 3858–3865, 1998 Google Scholar
Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M: Phase 1 study of ixinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12: 90–96, 1994 Google Scholar
Mori K, Hirose T, Machida S, Yokoyama K, Tominaga K: A phase I study of irinotecan anf infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur J Cancer 33: 503–505, 1997 Google Scholar
Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A, Okamato H, Nakashima H, Ohmatsu H, Shiraishi J, Nomura N, Saijo N: Phase 1 clinical trial of irinotecan (CPT-II), 7-ethyl-10-[4-(Ipiperidino)-1-piperidino]carbonyloxy-campothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 54: 2636–2642, 1994 Google Scholar
Sugiura S, Saka H, Ando M, Minami H, Watanabe A, Nomura F, Yamamoto M, Sakai S, Nishiwaki K, Shimokata K: Phase 1 dose escalation study of carboplatin (CBDCA) and irinotecan (CPT-II) (abstract). Proc ASCO 16: 252a, 1997 Google Scholar
Mick R, Gupta E, Vokes E, Ratain MJ: Limited sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliairy index and intestinal toxicity. J Clin Oncol 14: 2012–2019, 1996 Google Scholar
Stewart CF, Zamboni WC, Crom WR, Houghton PJ: Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 40: 259–265, 1997 Google Scholar
Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML: Phase 1 and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17: 685–696, 1999 Google Scholar
Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J: Pharmacokinetic interrelationships of irinotecan (CPT-II) and its three major plasma metabolites in patients enrolled in phase 1–2 trials. Clin Cancer Res 3: 1261–1266, 1997 Google Scholar
Rothenberg ML: Topoisomerase 1 inhibitors: Review and update. Ann Oncol 8: 837–855, 1997 Google Scholar
Supko JG, Plowman J, Dykes DJ, Zaharko DS: Relationship between the schedule dependence of 9-AC antitumor activity in mice and its plasma pharmacokinetics (abstract). Proc ASCO 33: 432, 1992 Google Scholar
Supko JG, Malspeis L: Pharmacokinetics of the 9-amino and 10,11-metylenedioxy derivates of camptothecin in mice. Cancer Res 53: 3062–3069, 1993 Google Scholar
Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D, Kufe D: A phase 1 and pharmacokinetic study of a new camptothecin derivate, 9-aminocamptothecin. Clin Cancer Res 1: 269–271, 1995 Google Scholar
Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Liebermann R, Liang M, Corse W, Grem J: Phase 1 and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14: 1236–1244, 1996 Google Scholar
Takimoto CJ, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL: Pharmacokinetics and phannacodynamics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15: 1492–1501, 1997 Google Scholar
Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ: Phase 1 and pharmacologic study of 9 aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 16 1122–1130, 1998 Google Scholar
Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW: Phase 1 trial of the colloidal dispersion formulation of 9-amino20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res 4: 317–324, 1998 Google Scholar
Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ: Phase 1 clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 42: 84–87, 1998 Google Scholar
Pastori A, Farao M, Geroni C, Porro MG, Grandi M: Antitumor activity of 9-AC by s.c. and oral route (abstract). Proc AAC1R38: 18, 1997 Google Scholar
Sparreboom A, de Jonge MJA, Punt CJA, Nooter K, Loos W, Porro MG, Verweij J: Pharmacokinctics and bioavailability of oral 9-AC capsules in adult patients with solid tumors. Clin Cancer Res 4: 1915–1919, 1998 Google Scholar
Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ: Phase 1 and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation every 5 weeks. J Clin Oncol 16: 1120–1130, 1998 Google Scholar
Sparreboom A, de Jonge MJA, Punt CJA, Loos W, Nooter K, Stoter G, Porro MG, Verweij J: Prediction of the systemic exposure to oral 9-AC using single-sample analysis. Drug Metab Dispos 27: 816–820, 1999 Google Scholar
Hinz HR, Harris NJ, Natelson EA, Giovanella BC: Pharmacokinetics of the _in vivo_and _in vitro_conversion of 9-NC to 9-AC in humans, dogs and mice. Cancer Res 34: 3096–3100, 1994 Google Scholar
Pantazis P, Harris N, Mendoza JT, Giovanella B: Conversion of 9-NC to 9-AC by human blood cells in vitro. Eur J Hemat 53: 246–248, 1994 Google Scholar
Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC: Camptothecin derivates induce regression of human ovarian carcinomas grown in nude mice and distinguish between non tumorigenic and tumorigcnic cells in vitro. Int J Cancer 53: 863–871, 1993 Google Scholar
Verschraegen CF, Natelson E, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, and Stehlin JS: A phase 1 clinical and pharmacological study of oral 9-NC, a novel water soluble topoisomerase inhibitor. Anti-Cancer Drugs 9: 36–44, 1998 Google Scholar
Verschraegen C, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman R, Edwards C, Harris N, Steger M, Steltz V, Giovanella BC, Stehlin JS: A phase 2 study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anti-Cancer Drugs 10: 375–384, 1999 Google Scholar
Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS: Phase 1 and pharmacological studies of 20-(S)camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803: 224–230, 1996 Google Scholar
Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MJ, Jonson RK: Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase 1. Cancer Res 48: 6404–6410, 1998 Google Scholar
Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T: Elevated expression of DNA topoisomerase 2 in camptothecinresistant human tumor cell lines. Cancer Res 50: 7962–7965, 1990 Google Scholar
Toppmeyer D, Gupta E, Saleem A, Zamek R, Much J, Ibrahim N, Bindi M, Haluska P, Li X-G, Goodin S, Aisner J, Natelson E, Giovanella B, Rubin E: A phase 1 pharmacokinetic and pharmacodynamic study of camptothecin and etoposide in patients with advanced malignancies (abstract). Proc ASCO 16: 203a, 1997 Google Scholar
Gupta E, Ahmad FY, Cook TJ, Saleem A, Li X-G, Zamek R, Toppmeyer D, Sinko PJ, Rubin EH: Optimizing administration of oral camptothecins: intestinal pcrmeability of lactone and total 20-(S)-camptothecin (abstract). Proc ASCO 16: 237a, 1997 Google Scholar
Emerson DL, McIntyre G, Luzzio M, Wissel PS: Preclinical antitumor activity of a novel water-soluble camptothecin analog (GI147122 c). Ann Oncol 5: 185, 1994 Google Scholar
Gerrits CJH, Creemers GJ, Schellens JHM, Wissel P, Planting ASTh, Kunka R, Selinger K, de Boer-Dennert M, Marijnen Y, Harteveld M, Verweij J: Phase 1 and pharmacologic study of the new topoisomerase 1 inhibitor GI147221, using a daily _ 5 intravenous administration. Br J Cancer 73: 744–750, 1996 Google Scholar
Paz-Ares L, Kunka R, DeMaria D, Cassidy J, Alden M, Beranek P, Kaye S, Littlefield D, Reilly D, Depee S, Wissel P, Twelves C, O'Dwyer P: A phase 1 clinical and pharmacologic study of the new topoisomerase 1 inhibitor GI147211 given as a 72 hour continuous infusion. Br J Cancer 78: 1329-1336, 1998 Google Scholar
Gerrits CJH, Schellens JHM, Creemers GJ, Wissel P, Planting ASTh, Pritchard JF, DePee S, de Boer-Dennert M, Harteveld M, Verweij J: The bioavailability of oral GI14721 (GG211), a new topoisomerase 1 inhibitor. Br J Cancer 76: 946–951, 1997 Google Scholar
Kasprzyk PG, Demarquay D, Lesueru-Ginot L, Carlson M, Lauer J, Huchet M, Coulomb H, Camara J, Lavergne O, Bigg DH: An E-ring modified camptothecin, BN-80915, shows unusual stability and high activity both _in vitro_and in vivo. Proc AACR 40: 739, 1999 Google Scholar
Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115, 1997 Google Scholar
DeMario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J Clin Oncol 16: 2557–2567, 1998 Google Scholar
van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Brokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH: Pharmacokinetics of topotecan given on a daily-times-five schedule in phase 2 trials using a limited sampling procedure. Cancer Chemother Pharmacol 38: 254–260, 1996 Google Scholar